Trump says pharmaceutical, copper tariffs coming ‘very soon’

While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.

Lilly gets FDA OK of modified dosing for Alzheimer’s drug

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

Get your brand in front of biotech & pharma execs

Gilead signs lenacapavir access deal; Arvinas CEO to step down

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

Actithera draws new investors to radiopharma drug pitch

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Protein degraders: chasing undruggable targets

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.